Characterisation of Low Frequency Hearing and Vestibular Function in Patients Undergoing Cochlear Implantation

Sponsor
Aalborg University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06021132
Collaborator
(none)
80
1
46
1.7

Study Details

Study Description

Brief Summary

The study will follow a cohort of CI-candidates becoming CI-user, till two years postoperative. A through-out assessment of both their audiological and vestibular status will be carried out at multiple fixed timepoints over 2 years, evaluating both subjective (patients reported) and objective outcomes over time. For the audiological part of the study both pure-tone and speech audiometry results will be held against the patient perceived benefit of the treatment as assessed by the questionnaires NCIQ and SSQ-12. The vestibular part of the study will evaluate the function of the SCCs and the sacculus. This is will be put in concert with functional tests of the vestibular system, and the patient perceived outcome measure DHI. Correlations between vestibular and audiological performances will be examined. A collection of specific hypotheses will be tested by predefined statistical methods.

Condition or Disease Intervention/Treatment Phase
  • Device: cochlear implant

Study Design

Study Type:
Observational
Anticipated Enrollment :
80 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Characterisation of Low Frequency Hearing and Vestibular Function in Patients Undergoing Cochlear Implantation
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Feb 28, 2026

Outcome Measures

Primary Outcome Measures

  1. Anticipated increase in speech audiometric performances [+24 months from last inclusion. Expected to be complete in juli 2025.]

    The preoperative status will be held against their performance at 6, 12 and 24 months. Yet the performance at 6 months will also be held against status at 24 months

  2. Anticipated increase in patient reported outcome measures [+24 months from last inclusion. Expected to be complete in juli 2025.]

    The preoperative status will be held against their performance at 6, 12 and 24 months. Yet the performance at 6 months will also be held against status at 24 months

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults (At or above 18 years of age and capable of giving an informed consent)

  • Cochlear implant candidacy

  • Profound bilateral post-lingual hearing loss

  • Proficiency in Danish

  • Expected ability to participate on both all pre- and postoperative examinations

  • No previous CI experiences

Exclusion Criteria:
  • Later abandonment of CI candidacy

  • Blindness or visual handicap compromising eye movement evaluation

  • Distinct neck mobility handicap hindering either vHIT- or cVEMP examination

  • Patient reluctance, such as consistent no-show or cancellations of appointments

  • CI-surgery before preoperative evaluation could be obtained

  • Simultaneous bilateral cochlea implantation.

  • Sequential CI within the follow-up period

Contacts and Locations

Locations

Site City State Country Postal Code
1 Balance & Dizziness Centre, Department of Otolaryngology, Head & Neck Surgery and Audiology, Aalborg University Hospital Aalborg Denmark 9000

Sponsors and Collaborators

  • Aalborg University Hospital

Investigators

  • Principal Investigator: Jonas B Kjlærsgaard, MD, ENT department, Aalborg University Hospital
  • Study Director: Michael L Gaihede, PhD, MD, ENT department, Aalborg University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jonas Bruun Kjærsgaard, MD, Aalborg University Hospital
ClinicalTrials.gov Identifier:
NCT06021132
Other Study ID Numbers:
  • RN-86132
First Posted:
Sep 1, 2023
Last Update Posted:
Sep 1, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Jonas Bruun Kjærsgaard, MD, Aalborg University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 1, 2023